Phase 1 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have signed a consent form agreeing to take part in the trial
• People whose tumour tissue (from a stored sample) has been tested at the Hospital of the University of Pennsylvania and shows a protein called folate receptor alpha (FRα) on at least 10% of tumour cells
• People diagnosed with lung adenocarcinoma (a type of lung cancer) that has spread or come back, and who have a confirmed build-up of fluid around the lung caused by cancer (malignant pleural effusion)
• People whose lung cancer has already been treated with at least one standard treatment for advanced-stage disease, which did not work or stopped working
• People who have measurable signs of active cancer, based on standard imaging measurement guidelines (RECIST 1.1)
• People who have had brain metastases (cancer that spread to the brain) that have already been treated, are not currently being treated, are not getting worse on scans, and who are no longer taking steroids for that brain condition — provided there is no cancer along the spinal fluid pathways or pressure on the spinal cord
• People whose kidneys, liver, lungs, and heart are working well enough, based on blood tests and scans (confirm specific values with trial site)
• People aged 18 or older
• People who are in reasonably good general health, able to carry out daily activities with little or no limitation (ECOG performance status 0 or 1)
• People whom their treating doctor considers a possible candidate for a standard immunotherapy treatment called a checkpoint inhibitor

Who may not be able to join:

• People who have a significant build-up of fluid around the lung that cannot be drained using standard medical procedures
• People whose scans show cancer spread through the lymph channels of more than one lobe of the lung, or signs of extensive cancer spread throughout both lungs
• People with signs of active lung inflammation caused by previous radiation treatment
• People whose scans show underlying scarring or inflammation of the lung tissue (interstitial lung disease), including damage caused by previous medications
• People with an active hepatitis B or hepatitis C infection
• People with any other active infection that is not under control
• People with severe heart failure (Class III or IV by standard medical classification)
• People who have had another invasive cancer within the past two years (though some non-invasive skin cancers treated with curative intent may still be considered — confirm with trial site)
• People who rely on steroid tablets or other immune-suppressing medications on an ongoing basis
• People who are pregnant or breastfeeding; people who could become pregnant must agree to use an acceptable form of contraception
• People with an active autoimmune disease that requires immune-suppressing treatment at a significant dose, or people with autoimmune conditions affecting the nervous system (such as multiple sclerosis)
• People who have had an allergic reaction to any of the ingredients in the study treatment, including human serum albumin, DMSO, or Dextran 40

Important: Always verify eligibility with the trial site directly before applying.